A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
1상
완료
NCT06023095
| 대상 질환 | Overweight, Obesity |
|---|
| 임상 단계 | 1상 |
|---|
| 스폰서 | Eli Lilly and Company |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 24 명 |
|---|
| 중재(약물) | LY3502970 |
|---|
| 시작일 | 2023년 9월 21일 |
|---|
| 완료일 | 2024년 7월 29일 |
|---|
| 결과 공개일 | 2026년 7월 17일 |
|---|
요약
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2) · Participants
| LY3502970 (Cohort 1) | 10 Participants |
|---|
| LY3502970 (Cohort 2) | 8 Participants |
|---|
| Placebo | 3 Participants |
|---|
| LY3502970 (Cohort 1) | 0 Participants |
|---|
| LY3502970 (Cohort 2) | 0 Participants |
|---|
| Placebo | 0 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.